OncoPharm

Zolbetuximab

9 snips
Oct 31, 2024
A groundbreaking monoclonal antibody for gastric cancer is here! The podcast dives into the FDA approval of Zolbetuximab, detailing its mechanism, dosing, and clinical trial results. Patient experiences take center stage, particularly the challenge of managing side effects like vomiting during early treatment. The discussion also explores strategies to ease these issues, shed light on their impact on clinic visits, and consider broader implications in oncology. Tune in for fascinating insights into this innovative therapy!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Claudin 18.2 as Therapy Target

  • Claudin 18.2 is a tight junction protein visible in stomach cancer cells as they pull apart, allowing targeted monoclonal antibody therapy.
  • Zolbetuximab exploits this exposing of Claudin 18.2 to direct immune cell killing of cancer cells.
INSIGHT

Zolbetuximab's Cytolytic Mechanism

  • Zolbetuximab kills cells via antibody-dependent cytotoxicity rather than blocking pathways.
  • This cytolytic action is similar to rituximab, engaging immune mechanisms to destroy tumor cells.
INSIGHT

Clinical Benefits Observed

  • Clinical trials Spotlight and GLOW showed modest improvement in progression-free and overall survival with zolbetuximab plus chemo.
  • Survival benefit measured about 10% increase at two years, indicating meaningful but modest gains.
Get the Snipd Podcast app to discover more snips from this episode
Get the app